

In the specification:

Please delete the first paragraph of the specification and insert therefore:

--This application is a divisional of U.S. Application Ser. No. 09/809,517, filed Mar. 15, 2001, now U.S. Patent No. 6,753,136, the entire contents of which are expressly incorporated herein by reference, which is a continuation of PCT/EP00/06968, filed July 20, 2000. This application is based upon, and claims priority to, European patent applications EP 99 11 4072.4 filed July 20, 1999, and EP 00 10 3551.8, filed February 18, 2000, which are incorporated herein by reference in their entirety.--

Please delete the descriptions of Figures 8 and 9 on pages 17 and 18 of the specification and insert therefore:

**FIGURE 8: Detection of scFv MacI-5 displayed on engineered phages--Two-vector system**

Phages derived from constructs pMorphX7-MacI-5-LH / pBR-C-gIII (lanes 1 & 5), pMorphX7-MacI-5-LHC / pBR-C-gIII (lanes 2 & 6), pMorphX7-MacI-5-LHC (lanes 3 & 7) and pMorphX7-MacI-5-LH (lanes 4 & 8) were produced by standard procedures.  $1 - 5 \times 10^{10}$  phages were pre-incubated in PBS with DTT (lanes 1 - 4) or without DTT (lanes 5 - 8). SDS loading buffer lacking reducing agents was added, phages were applied to an 4-15% SDS PAA Ready gel and analysed in immunoblots. Detection of scFvs associated with phages was done via anti-FLAG M1 antibody, anti-mouse-IgG-AP conjugate and Fast BCIP/NPT substrate (Figure 8A) and via anti-pIII antibody, anti-mouse-IgG-AP conjugate and Fast BCIP/NPT substrate (Figure 8B). Low range marker (Amersham #RPN756) is marked as M. Experimental details are given in Example 2.1.

**FIGURE 9: Detection of scFvs displayed on engineered phages--One-vector system**

Phages derived from constructs pMorph18-C-gIII-hag2-LHC (lanes 1 - 8; Figure 9A), pMorph18-C-gIII-AB1.1-LHC (lanes 1, 2, 5 and 6; Figure 9B) and pMorph18-C-gIII-MacI-5-LHC (lanes 3, 4, 7 and 8; Figure 9B) were produced by standard procedures.  $1-5 \times 10^{10}$  phages were pre-incubated in PBS with DTT (lanes 1, 2, 5 and 6; Figure 9A and lanes 1 - 4; Figure 9B) or without DTT (lanes 3, 4, 7 and 8; Figure 9A and lanes 5 - 8; Figure 9B). SDS loading buffer lacking reducing agents was added, phages were applied to an 4-15% SDS PAA Ready gel and analysed in immunoblots. Detection of scFvs associated with phages was done via anti-FLAG M1 antibody, anti-mouse-IgG-AP conjugate and Fast BCIP/NPT substrate (lanes 1 - 4;

Figure 9A) and via anti-pIII antibody, anti-mouse-IgG-AP conjugate and Fast BCIP/NPT substrate (lanes 5 – 8; Figure 9A and lanes 1 –8; Figure 9B). Low range marker (Amersham #RPN756) is marked as M. Experimental details are given in Example 2.1.